|
|
Article: Discovery Laboratories Raises $27.M To Advance Surfactant.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
With promising early data from a Phase III support trial of its lead product Surfaxin in hand, Discovery Laboratories Inc. raised $27.5 million through a private placement to keep the development going at a steady rate.
Surfaxin, synthetically engineered to mimic natural human surfactant, could push existing, animal-derived products "off the market within three years," if approved and if the lessons of history hold true, said John Cooper, chief financial officer of Doylestown, Pa.-based Discovery.
Synthetics of "top-notch pharmaceutical quality" such as Surfaxin typically outdo animal-based products over time, since the latter ...
Related newspaper, magazine, and journal articles:
|
|
Article: Indevus Reports Interim Review of NEBIDO Phase III ...
M2 Presswire;
March 26, 2007 ;
700+ words
... ... update to its ongoing Phase III pharmacokinetic trial ... purpose of the current Phase III trial is to evaluate testosterone ... male hypogonadism. The Phase III pharmacokinetic trial ... summer," stated Glenn L. Cooper, M.D., chairman and ...
|
|